Long-acting GHRH analog
CJC-1295
Early human researchA modified GHRH analog engineered to last longer in the body.
Evidence
Early human research
Regulatory status
Not FDA-approved.
Class
Long-acting GHRH analog
What it is
CJC-1295 is a GHRH analog. The version with "DAC" (drug affinity complex) binds to albumin in the blood, which extends how long it stays active.
What the research shows
- Small human studies in the mid-2000s reported sustained increases in growth hormone and IGF-1 levels.
- Clinical development did not continue to approval.
Read the published research on PubMed →
Researched for
CJC-1295 is not FDA-approved for the uses people commonly discuss. Its safety and effectiveness in people have not been established. Talk to a licensed provider before making any decision.
Educational content, not medical advice. This page does not recommend or dose any substance.
Related peptides
GHRH analog
Tesamorelin
A growth-hormone-releasing hormone analog with a narrow FDA approval.
FDA-approved drugGHRH analogSermorelin
A short GHRH fragment with a long research history.
Human clinical trialsGrowth hormone secretagogueIpamorelin
A selective ghrelin-receptor agonist that stimulates growth hormone release.
Early human research